Pantop%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520ds

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that decreases gastric acid production. ## Primary Indications * Healing of erosive esophagitis * Maintenance of healing of erosive esophagitis * Symptomatic gastroesophageal reflux disease (GERD) * H. pylori eradication (in combination with antibiotics) * Zollinger-Ellison syndrome ## Adult Dosing * **Erosive Esophagitis:** 40 mg orally once daily for 4 to 8 weeks. For maintenance, 20 mg orally once daily. * **Symptomatic GERD:** 20 mg orally once daily for up to 4 weeks. * **H. pylori Eradication:** 40 mg orally twice daily for 7 to 14 days, in combination with amoxicillin and clarithromycin. * **Zollinger-Ellison Syndrome:** Starting dose 40 mg orally twice daily. Doses may be increased as clinically needed. Doses up to 240 mg daily have been administered. ## Pediatric Dosing * **Erosive Esophagitis (5 to 16 years):** 20 mg orally once daily for 4 weeks. If needed, treatment can be extended for another 4 weeks. * **Symptomatic GERD (5 to 16 years):** 20 mg orally once daily for up to 4 weeks. *Note: Dosing for pediatric patients younger than 5 years or for indications other than erosive esophagitis and symptomatic GERD may vary and should be based on specific protocols or expert consultation.* ## Dose Adjustments No dose adjustment is generally required for hepatic or renal impairment. ## Contraindications Known hypersensitivity to pantoprazole or any component of the formulation. ## Adverse Effects Common adverse effects include headache, diarrhea, nausea, dizziness, and abdominal pain. Long-term use may be associated with increased risk of: * Fractures (hip, wrist, spine) * Clostridium difficile infection * Vitamin B12 deficiency * Hypomagnesemia ## Key Drug Interactions * **Antiretrovirals (e.g., rilpivirine, atazanavir):** Pantoprazole may decrease absorption. Avoid coadministration or monitor closely. * **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. Consider interruption of pantoprazole during methotrexate treatment. * **Clopidogrel:** PPIs may reduce the antiplatelet effect of clopidogrel. Consider timing of administration or alternative therapy. * **CYP2C19 substrates (e.g., citalopram, diazepam):** Pantoprazole may inhibit CYP2C19, potentially increasing levels of these drugs. ## Monitoring * Monitor for symptom improvement. * Monitor electrolytes (magnesium, sodium, potassium) with prolonged therapy, especially if using diuretics or digoxin. * Assess for signs of C. difficile infection. * Monitor for bone fracture risk with long-term use. ## Clinical Pearls * Administer 30 minutes to 1 hour before a meal. * Delayed-release formulations should be swallowed whole and not chewed or crushed. * For patients unable to swallow intact tablets, pantoprazole for oral suspension is available. * Consider the potential for drug interactions, especially with concomitant medications metabolized by CYP2C19 or affecting absorption. * Long-term PPI use should be re-evaluated regularly to determine if continued therapy is necessary. --- *This information is for educational purposes and does not substitute for professional medical advice. Always consult the most current prescribing information and your healthcare provider for any medication-related decisions.*